Outcomes in COVID-19 astodrimer sodium studies

0 0.5 1 1.5+ All studies -205% 1 197 Improvement, Studies, Patients Relative Risk Hospitalization -205% 1 197 Viral clearance 24% 1 197 RCTs -205% 1 197 Early -205% 1 197 Astodrimer Sodium for COVID-19 c19early.org November 2025 Favorsastodrimer sodium Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) -205% 3.05 [0.13-74.0] hosp. 1/96 0/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Early treatment -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk All studies -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk 1 astodrimer sodium COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors astodrimer sodium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) -205% 3.05 [0.13-74.0] hosp. 1/96 0/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Early treatment -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk All studies -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk 1 astodrimer sodium COVID-19 hospitalization result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Favors astodrimer sodium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) -205% 3.05 [0.13-74.0] hosp. 1/96 0/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Early treatment -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk All studies -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk 1 astodrimer sodium COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors astodrimer sodium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) 19% 0.81 [0.52-1.26] no recov. 23/79 31/86 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Early treatment 19% 0.81 [0.52-1.26] 23/79 31/86 19% lower risk All studies 19% 0.81 [0.52-1.26] 23/79 31/86 19% lower risk 1 astodrimer sodium COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.35 Favors astodrimer sodium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) 24% 0.76 [0.47-1.27] viral+ 62/96 73/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0057 Early treatment 24% 0.76 [0.47-1.27] 62/96 73/101 24% lower risk All studies 24% 0.76 [0.47-1.27] 62/96 73/101 24% lower risk 1 astodrimer sodium COVID-19 viral clearance result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0057 Favors astodrimer sodium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) -205% 3.05 [0.13-74.0] hosp. 1/96 0/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Early treatment -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk All studies -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk 1 astodrimer sodium COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors astodrimer sodium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) -205% 3.05 [0.13-74.0] hosp. 1/96 0/101 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Early treatment -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk All studies -205% 3.05 [0.13-74.0] 1/96 0/101 205% higher risk 1 astodrimer sodium COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors astodrimer sodium Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Winchester (DB RCT) -205% 3.05 [0.13-74.0] hosp. 1/96 0/101 Improvement, RR [CI] Treatment Control Winchester (DB RCT) 19% 0.81 [0.52-1.26] no recov. 23/79 31/86 Winchester (DB RCT) 24% 0.76 [0.47-1.27] viral+ 62/96 73/101 Astodrimer sodium COVID-19 outcomes c19early.org November 2025 Favors astodrimer sodium Favors control